Preview

Epilepsy and paroxysmal conditions

Advanced search

ЭКСАЛИЕФ® – НОВЕЙШИЙ АНТИЭПИЛЕПТИЧЕСКИЙ ПРЕПАРАТ

Full Text:

Abstract

.

About the Author

Н. Ермоленко
Воронежская областная детская клиническая больница №1
Russian Federation


References

1. Ben-Menachem E. et al. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy. 2010; Res89: 278-285.

2. Cramer J. et al. Improvement in quality-of-life and depressive symptoms during long-term treatment with Eslicarbazepine acetate: BIA-2093-301 study. J. Neurol Neurosurg Psychiatry. doi: 10.1136/ jnnp-2013-306573.93 2013 84:e2.

3. Elger C., Bialer M., Cramer J.A., Maia J., Almeida L., Soares-da-Silva P. Eslicarbazepine acetate: A double-blind, add-on, placebo-controlled exploratory trial in adult patients with partialonset seizures. Epilepsia. 2007; 48: 497-504.

4. Gil-Nagel A., Lopes-Lima J., Almeida L., Maia J. and Soares-da-Silva P. Efficacy and safety of 800 and 1200 mg Eslicarbazepine acetate as adjunctive treatment in adults with refractorypartial-onset seizures. Acta Neurol Scand. 2009; 120: 281-287.

5. Halasz P., Cramer J.A., Hodoba D., Czlonkowska A., Guekht A., Maia J., Elger C., Almeida L. and Soares-da-Silva P. Long-term efficacy and safety of Eslicarbazepine acetate: Results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia. 2010; 51: 1963-1969.10.

6. Hufnagel A., Ben-Menachem E., Gabbai A.A, Falcao A., Almeida L. and Soares-da-Silva P. Long-term safety and efficacy of Esliicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: Results of a 1-year open-label extension study. Epilepsy Research. 2012; 103: 262-269.

7. Incidence of Rash and Hyponatraemia in Adult Patients with Refractory Partial Seizures Treated with Adjunctive Eslicarbazepine Acetate: Results From Three Phase III Studies And 1-Year Open-Label Extensions T. Nunes, C. Elger, E. Ben-Menachem, A. Gil-Nagel, J. Maia1, P. Soares-da-Silva 1BIAL – Portela & Co, SA, S Mamede do Coronado, Portugal; 2University of Bonn, Bonn, Germany; 3Sahlgren University Hospital, Göteborg, Sweden; 4Hospital Ruber Internacional, Madrid, Spain.

8. Gil-Nagel A., Elger C., Ben-Menachem E. et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focalonset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia. 2013; 54 (1): 98-107.

9. Kanner A.M. Depression and epilepsy: a review of multiple facets of their close relation. Neurol Clin. 2009; 27 (4): 865 80.

10. 10. Holtkamp M. et al. Eslicarbazepine acetate as add-on treatment to antiepileptic monotherapy in adults with partial-onset seizures: realworld data from the EPOS study. Poster presented at IEC 2015, Istambul, Turkey.

11. Derambure P. et al. Eslicarbazepine acetate as add-on to antiepileptic monotherapy in adults with partial-onset seizures (EPOS study): analysis by baseline antiepileptic drug. Poster presented at IEC 2015, Istambul, Turkey


For citation:


. . Epilepsy and paroxysmal conditions. 2015;7:8-10. (In Russ.)

Views: 79


ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)